US2543674A - Blood anticoagulant composition - Google Patents
Blood anticoagulant composition Download PDFInfo
- Publication number
- US2543674A US2543674A US47534A US4753448A US2543674A US 2543674 A US2543674 A US 2543674A US 47534 A US47534 A US 47534A US 4753448 A US4753448 A US 4753448A US 2543674 A US2543674 A US 2543674A
- Authority
- US
- United States
- Prior art keywords
- vitamin
- dicoumarol
- blood
- anticoagulant
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
Definitions
- This invention relates to new compositions which are particularly adapted to reduce Or prevent clotting of the blood, and more particularly refers to compositions of dicoumarol and a compound which induces clotting of the blood.
- dicoumarol is a most eliective anticoagulant. Unfortunately its use has been seriously curtailed because it is so powerful in its action that there is an ever present danger of hemorrhaging on the part Of the patient. If a slight excess of dicoumarol is administered, hemorrhaging is likely to occur. Thus, the use of this material, despite its valuable anticoagulant property, is subject to serious consequences in the event of a slight overdose. The problem is further complicated by the fact that a dosage of dicoumarol which might be satisfactory on one day would be too much the following day. This is due to the fact that the body synthesizes vitamin K and this counteracts the efiect of the dicoumarol.
- compositions containing dicoumarol which, while preserving its exceptional anticoagulant properties, at the same time minimize the danger of an overdose, thereby permitting its widespread use without meticulous controls.
- composition which is effective in treating or preventing clotting of the blood, we may mix 100 milligrams of dicoumarol and 8 milligrams of menadione. Where a greater anticoagulant effect is desired, the amount of dicoumarol may be increased accordingly, and the converse is likewise true.
- vitamin P may be used in the form of hesperidin, hesperidin methyl chalcone, and phosphorylated hesperidin.
- the advantage of employing this material is that it further minimizes the possibility of hemorrhaging, since it strengthens the structure of the blood vessels, and as long as these vessels are prevented from rupturing there can be no hemorrhage.
- composition employing vitamin P is as folows:
- the prothrombin level of the blood for each patient may be determined in accordance with customary procedure, and a composition of dicoumarol and vitamin K prepared to produce an anticoagulant effect in that patient. Due to the large vitamin K content of this composition there is practically no likelihood that the patient will hemorrhage as the result of subsequent variations in the amount of vitamin K synthesized in the patients body.
- compositions are particularly adapted for use in the prophylaxis and treatment of intravascular clotting, in postoperative, post-traumatic and postinfectious thrombophlebitis, pulmonary embolism, acute embolic or thrombotic occlusion of peripheral arteries, recurrent idiopathic thrombophlebitis, and the like.
- An anticoagulant composition comprising approximately 100 parts of dicoumarol, approximately 8 parts of 2-methy1-1,4-naphthoquinone and approximately from 10 to 20 parts of a member of the class consisting of hesperidin, hesperidin methyl chalcone and phosphorylatedhesperidin.
Description
Patented Feb. 27, 1951' BLOOD ANTICOAGULANT COMPOSITION Vinton R. Swayne, Jr., and Gustav J. Martin, Philadelphia, Pa, assignors to The National Drug Company, Philadelphia, Pa., a corporation of Pennsylvania No Drawing. Application September 2, 1948,
Serial No. 47,534
This invention relates to new compositions which are particularly adapted to reduce Or prevent clotting of the blood, and more particularly refers to compositions of dicoumarol and a compound which induces clotting of the blood.
It is known that dicoumarol is a most eliective anticoagulant. Unfortunately its use has been seriously curtailed because it is so powerful in its action that there is an ever present danger of hemorrhaging on the part Of the patient. If a slight excess of dicoumarol is administered, hemorrhaging is likely to occur. Thus, the use of this material, despite its valuable anticoagulant property, is subject to serious consequences in the event of a slight overdose. The problem is further complicated by the fact that a dosage of dicoumarol which might be satisfactory on one day would be too much the following day. This is due to the fact that the body synthesizes vitamin K and this counteracts the efiect of the dicoumarol. Synthesis of vitamin K by the body, however, varies from day to day, and may vary from a few micrograms per day up to as much as two or three milligrams. With such an extreme variation in the amount of vitamin K produced by the body, it is readily apparent that to determine the optimum dosage of dicoumarol is almost an impossible task. Hence the refusal of many doctors to employ this unusually effective anticoagulant.
It is an object of this invention to produce compositions containing dicoumarol which, while preserving its exceptional anticoagulant properties, at the same time minimize the danger of an overdose, thereby permitting its widespread use without meticulous controls. Add tional objects will become apparent from a consideration of the following description and claim;
In accordance with our invention, we have found that the effectiveness of dicoumarol is dependent to a large extent upon the ratio between the dicoumarol and the vitamin K present in the body. Where the amount of vitamin K is extremely small the ratio between the two is of course very large and a slight variation in the amount of vitamin K produced in the body results in a substantial change in this ratio. By means of our invention we prepare compositions of dicoumarol containing substantial amounts of vitamin K or one of the known substitutes for this material, such as menadione. The d1- coumarol is present in these compositions in an amount greater than that needed to overcome the effect of the vitamin K and produces a net anticoagulant efiect. Because of the presence 1 Claim. (01. 16765) of substantial amounts of vitamin K it is at once evident that the ratio in the body between the dicoumarol and the vitamin K will be but slightly changed by any variation in the amount of vitamin K which is naturally synthesized. As a result, our compositions, for all practical purposes, minimize the extreme clients heretofore resulting from the natural synthesis of vitamin K during administration of dicourmarol.
In view of the expense attendant upon the use of vitamin K, it is advisable to use one of the cheaper substituteswhich are known to possess the same blood coagulating properties. Menadione, which is Z-methyl-l,4;-nanhthoquinone, as well as other vitamin K substitutes or mixtures thereof, may be used for this purpose.
We prefer to use in our compositions approximately parts by weight of dicoumarol and approximately 8 parts by weight of menadione.
If naturally occurring vitamin K were used in place of menadione. the amount thereof would be decreased to compensate for its greater coagulant effectiveness. It is to be understood that the foregoing ratio may be varied widely without departing from the scope of this invention.
As an example of the composition which is effective in treating or preventing clotting of the blood, we may mix 100 milligrams of dicoumarol and 8 milligrams of menadione. Where a greater anticoagulant effect is desired, the amount of dicoumarol may be increased accordingly, and the converse is likewise true.
As a preferred embodiment of our invent on, we may likewise incorporate in the compositions referred to previously vitamin P to produce a strengthening of the capillary walls, thereby reducing the possibility of rupture. For this purpose vitamin P may be used in the form of hesperidin, hesperidin methyl chalcone, and phosphorylated hesperidin. The advantage of employing this material is that it further minimizes the possibility of hemorrhaging, since it strengthens the structure of the blood vessels, and as long as these vessels are prevented from rupturing there can be no hemorrhage.
1 A composition employing vitamin P is as folows:
Milligrams Dicoumarol 100 Menadione 8 Hesperidin methyl chalcone 10-20 By means of our invention the prothrombin level of the blood for each patient may be determined in accordance with customary procedure, and a composition of dicoumarol and vitamin K prepared to produce an anticoagulant effect in that patient. Due to the large vitamin K content of this composition there is practically no likelihood that the patient will hemorrhage as the result of subsequent variations in the amount of vitamin K synthesized in the patients body.
Our compositions are particularly adapted for use in the prophylaxis and treatment of intravascular clotting, in postoperative, post-traumatic and postinfectious thrombophlebitis, pulmonary embolism, acute embolic or thrombotic occlusion of peripheral arteries, recurrent idiopathic thrombophlebitis, and the like.
As many apparently widely different embodiments of this invention may be made without departing from the spirit and scope hereof, .itis to be understood that the invention is not limited to the specific embodiments hereof except asdefined in the appended claim.
We claim:
An anticoagulant composition comprising approximately 100 parts of dicoumarol, approximately 8 parts of 2-methy1-1,4-naphthoquinone and approximately from 10 to 20 parts of a member of the class consisting of hesperidin, hesperidin methyl chalcone and phosphorylatedhesperidin.
VIN'ION R. SWAYNE, JR. GUSTAV J. MARTIN.
REFERENCES CITED The following references are of record in the file of this patent:
Cromer, Proceedings of the Stair meetings of theMayo Clinic, vol. 19, May 3, 1944, No. 9, pages 217-223.
Davidson, Amer. J. Med. Science, vol. 210 (1945), pages 634-637.
Andersen et al., A Survey of Pharmacology and Experimental Therapeutics 1947, page 148.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47534A US2543674A (en) | 1948-09-02 | 1948-09-02 | Blood anticoagulant composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47534A US2543674A (en) | 1948-09-02 | 1948-09-02 | Blood anticoagulant composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US2543674A true US2543674A (en) | 1951-02-27 |
Family
ID=21949525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US47534A Expired - Lifetime US2543674A (en) | 1948-09-02 | 1948-09-02 | Blood anticoagulant composition |
Country Status (1)
Country | Link |
---|---|
US (1) | US2543674A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2888381A (en) * | 1955-09-01 | 1959-05-26 | Us Vitamin Corp | Solutions of citrus bioflavonoids |
US2961376A (en) * | 1955-06-14 | 1960-11-22 | Internat Hormones Inc | Hemostatic composition |
US3219531A (en) * | 1960-08-04 | 1965-11-23 | Ind Chimique Sa | Flavone derivatives |
US3264378A (en) * | 1962-04-09 | 1966-08-02 | Armour Pharma | Serine ester of diacyl glycerol phosphate |
US3903266A (en) * | 1972-05-03 | 1975-09-02 | Ralph C Robbins | Compositions and methods for disaggregating blood cells |
US4271122A (en) * | 1978-04-27 | 1981-06-02 | Hoffmann-La Roche Inc. | Control plasma |
-
1948
- 1948-09-02 US US47534A patent/US2543674A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
None * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2961376A (en) * | 1955-06-14 | 1960-11-22 | Internat Hormones Inc | Hemostatic composition |
US2888381A (en) * | 1955-09-01 | 1959-05-26 | Us Vitamin Corp | Solutions of citrus bioflavonoids |
US3219531A (en) * | 1960-08-04 | 1965-11-23 | Ind Chimique Sa | Flavone derivatives |
US3264378A (en) * | 1962-04-09 | 1966-08-02 | Armour Pharma | Serine ester of diacyl glycerol phosphate |
US3903266A (en) * | 1972-05-03 | 1975-09-02 | Ralph C Robbins | Compositions and methods for disaggregating blood cells |
US4271122A (en) * | 1978-04-27 | 1981-06-02 | Hoffmann-La Roche Inc. | Control plasma |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Walker et al. | Adrenal medullary secretion in hemorrhagic shock | |
Nilsson et al. | Further studies on the effect of dextran of various molecular weight on the coagulation mechanism | |
US2543674A (en) | Blood anticoagulant composition | |
MXPA05009914A (en) | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides. | |
Hossman et al. | A randomized, placebo controlled trial of prostacyclin (PGI2) in peripheral arterial disease | |
Kochakian | The effect of dose and nutritive state on the renotrophic and androgenic activities of various steroids | |
KATO et al. | Metabolic differences of strychnine in the rat in relation to sex | |
CH661439A5 (en) | MODIFIED GLYCOSAMINOGLICANS EQUIPPED WITH ANTI-THROMBOTIC ACTIVITY. | |
Atkinson et al. | Inhibition of platelet aggregation by ketamine hydrochloride | |
US3548052A (en) | Heparin compositions and methods of using same | |
US3374144A (en) | Ophthalmic composition | |
Rosenthal et al. | PTA (factor XI) levels and coagulation studies after plasma infusions in PTA-deficient patients | |
Yardumian et al. | Platelet hyperaggregability occurring during prolonged continuous intravenous infusions of prostacyclin analogue ZK 36374 | |
US3446894A (en) | Stabilization of vitamin c tablets | |
Lovegrove et al. | Sympathoadrenal system and response of heart to acute exchange anemia | |
Johansson | Apparent resistance to oral anticoagulant therapy and influence of hypnotics on some coagulation factors | |
TW201813639A (en) | Uses of niclosamide and derivatives thereof | |
Neuhof et al. | THE INTRAMUSCULAR ADMINISTRATION OF SODIUM CITRATE A NEW METHOD FOR THE CONTROL OF BLEEDING | |
US3449494A (en) | Anti-inflammatory compositions containing a corticoidal steroid and a testololactone | |
US2376795A (en) | Sulphapyridine composition of low toxicity | |
US2485501A (en) | Chemotherapeutic agents | |
Yoshimura et al. | Blood coagulation and vascular integrity: effects of heparin | |
Martin | The mechanism of the action of dicarboxylic acids in blood coagulation | |
US1830313A (en) | Synergized hypnotic and sedative | |
US2363541A (en) | Detoxicant |